^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Excerpt:
...- Availability of paraffin blocks or slides to allow determination of EGFR amplification status...
Trial ID:
Source:
Title:
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Excerpt:
For PFS...EGFR gene amplification was borderline significant for poor outcome in the entire study group (P = .048)...
DOI:
10.1200/JCO.2008.17.5984
Trial ID:
Source:
Title:
Glioblastoma Multiforme With CDKN2A, Loss of PTEN and EGFR Amplification, and Diffuse Distant Organ Metastasis Treated With Six Lines of Therapy: A Case Report and Literature Review
Published date:
04/03/2022
Excerpt:
...although erlotinib and everolimus were given based on genetic test results, there was no response….There is no clear relationship between EGFR amplifications and survival in GBM. In our patient, we could not get a response from the erlotinib treatment given due to EGFR amplification.
DOI:
10.7759/cureus.23796
Source:
Title:
Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
Excerpt:
On the whole, 13 treatments were Avatar directed, and in 11 the Avatar response mimicked the patient response, predicting 2 progressive disease, 1 complete response, 6 partial response, and 2 stable disease (Table 3).
DOI:
10.1158/1078-0432.CCR-13-3047
